Bone Biologics (BBLG) Director Robert E. Gagnon Receives Award

What Happened

• Robert E. Gagnon, a director of Bone Biologics Corp (BBLG), was granted a derivative equity award on 2026-09-28 representing 113,896 shares. The Form 4 reports the acquisition price as $0.00 (no cash changed hands at grant). This filing reflects an award/grant of option-like rights rather than a market purchase or sale.

Key Details

• Transaction date: 2026-09-28; Form 4 filed: 2026-09-30 (timely filing).
• Amount granted: 113,896 derivative securities (reported at $0.00).
• Shares owned after the transaction: not specified in the filing.
• Footnotes: (1) Award granted under the Bone Biologics Corporation 2015 Equity Incentive Plan and, except as otherwise provided in the award notice, vests in four equal quarterly installments. (2) The option is noted as fully exercisable as of the date of this report.
• Transaction type code: A (award/grant of derivative securities).

Context

• This transaction is a compensation-related equity award (derivative/option rights) rather than an open-market buy or sale—such grants are common for directors and employees. Because the award is derivative, it gives the holder a right to acquire common stock in the future (subject to any vesting or exercise terms). The filing does not indicate an immediate sale of shares or a cashless exercise.